IPHA - יחס חוב להיוון בספרים Innate Pharma S.A.

The price action of Innate Pharma S.A. (IPHA) on the GURU.Markets platform, which currently stands at 0.00, reflects the dynamics of a business implementing AI and robotics for antibody creation. However, geopolitical fragmentation is hindering global testing and the supply of bio-resources. The company's growth relies on a strategic alliance with leading oncology centers, enabling the funding of scientific research without the need for merger and acquisition deals.

This metric determines the proportion of borrowed funds relative to the total value of assets minus liabilities, measuring the business's degree of financial autonomy. By analyzing the level of debt concentration within the balance sheet capitalization, an investor assesses the risk of credit pressure, which is critically important for Innate Pharma S.A. (IPHA), whose stability is supported by strategic alliances with big pharma and the retention of a unique staff of NK-cell researchers.